Autologous peripheral blood stem cell transplantation for patients with malignancies

The tri-service general hospital experience

Y. C. Chen, E. J. Hsueh, C. L. Ho, W. Y. Kao, H. L. Wan, T. Y. Chao

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background. High-dose chemotherapy/radiotherapy followed by autologous peripheral blood stem cells transplantation (APBSCT) can be used to treat chemosensitive malignant diseases. We retrospectively studied the APBSCT treatment efficacy and safety of patients at Tri-Service General Hospital (TSGH). Methods. From January 1994 to March 2000, 11 patients were treated with high doses of chemotherapy/radiotherapy followed by APBSCT. Nine patients were male and 2 were female. The median age was 26 years, with a range of 21 to 51. There were 7 acute myeloid leukemia (AML), 3 non-Hodgkin's lymphoma (NHL) and 1 ovarian cancer. All patients received both chemotherapy and granulocyte-colony stimulating factor to mobilize hematopoietic stem cells, and the most commonly used conditioning regimen was combined chemotherapy with Busulfan and Cyclophosphamide. Results. The median numbers of infused mononuclear and CD34+ cells were 3.19 × 108/kg and 9.2 × 106/kg, respectively. Nine of the 11 patients engrafted successfully, but 2 patients with AML failed to engraft. The median times of WBC recovery (ANC ≥ 500/uL) and platelet recovery (≥ 20 × 103/uL) were 13 and 16 days, respectively. Four patients with AML survived after APBSCT and two of them were alive and disease-free for 36 and 51 months, respectively. One patient with AML and 3 patients with NHL died of relapse, and one patient with ovarian cancer was alive but with disease at 50 months. Conclusions. For patients with AML, APBSCT may be an alternative, safe and useful treatment modality. Further strategies for reducing relapse in lymphoma patients merit further investigation.

Original languageEnglish
Pages (from-to)395-402
Number of pages8
JournalChinese Medical Journal (Taipei)
Volume64
Issue number7
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Peripheral Blood Stem Cell Transplantation
General Hospitals
Acute Myeloid Leukemia
Neoplasms
Drug Therapy
Ovarian Neoplasms
Non-Hodgkin's Lymphoma
Radiotherapy
Recurrence
Busulfan
Granulocyte Colony-Stimulating Factor
Patient Safety
Hematopoietic Stem Cells
Cyclophosphamide
Lymphoma
Blood Platelets

Keywords

  • Acute myeloid leukemia
  • Autologous peripheral blood
  • Non-Hodgkin's lymphoma
  • Stem cell transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Autologous peripheral blood stem cell transplantation for patients with malignancies : The tri-service general hospital experience. / Chen, Y. C.; Hsueh, E. J.; Ho, C. L.; Kao, W. Y.; Wan, H. L.; Chao, T. Y.

In: Chinese Medical Journal (Taipei), Vol. 64, No. 7, 2001, p. 395-402.

Research output: Contribution to journalArticle

@article{3094739e89a54c6bb7f19af96c32c818,
title = "Autologous peripheral blood stem cell transplantation for patients with malignancies: The tri-service general hospital experience",
abstract = "Background. High-dose chemotherapy/radiotherapy followed by autologous peripheral blood stem cells transplantation (APBSCT) can be used to treat chemosensitive malignant diseases. We retrospectively studied the APBSCT treatment efficacy and safety of patients at Tri-Service General Hospital (TSGH). Methods. From January 1994 to March 2000, 11 patients were treated with high doses of chemotherapy/radiotherapy followed by APBSCT. Nine patients were male and 2 were female. The median age was 26 years, with a range of 21 to 51. There were 7 acute myeloid leukemia (AML), 3 non-Hodgkin's lymphoma (NHL) and 1 ovarian cancer. All patients received both chemotherapy and granulocyte-colony stimulating factor to mobilize hematopoietic stem cells, and the most commonly used conditioning regimen was combined chemotherapy with Busulfan and Cyclophosphamide. Results. The median numbers of infused mononuclear and CD34+ cells were 3.19 × 108/kg and 9.2 × 106/kg, respectively. Nine of the 11 patients engrafted successfully, but 2 patients with AML failed to engraft. The median times of WBC recovery (ANC ≥ 500/uL) and platelet recovery (≥ 20 × 103/uL) were 13 and 16 days, respectively. Four patients with AML survived after APBSCT and two of them were alive and disease-free for 36 and 51 months, respectively. One patient with AML and 3 patients with NHL died of relapse, and one patient with ovarian cancer was alive but with disease at 50 months. Conclusions. For patients with AML, APBSCT may be an alternative, safe and useful treatment modality. Further strategies for reducing relapse in lymphoma patients merit further investigation.",
keywords = "Acute myeloid leukemia, Autologous peripheral blood, Non-Hodgkin's lymphoma, Stem cell transplantation",
author = "Chen, {Y. C.} and Hsueh, {E. J.} and Ho, {C. L.} and Kao, {W. Y.} and Wan, {H. L.} and Chao, {T. Y.}",
year = "2001",
language = "English",
volume = "64",
pages = "395--402",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "7",

}

TY - JOUR

T1 - Autologous peripheral blood stem cell transplantation for patients with malignancies

T2 - The tri-service general hospital experience

AU - Chen, Y. C.

AU - Hsueh, E. J.

AU - Ho, C. L.

AU - Kao, W. Y.

AU - Wan, H. L.

AU - Chao, T. Y.

PY - 2001

Y1 - 2001

N2 - Background. High-dose chemotherapy/radiotherapy followed by autologous peripheral blood stem cells transplantation (APBSCT) can be used to treat chemosensitive malignant diseases. We retrospectively studied the APBSCT treatment efficacy and safety of patients at Tri-Service General Hospital (TSGH). Methods. From January 1994 to March 2000, 11 patients were treated with high doses of chemotherapy/radiotherapy followed by APBSCT. Nine patients were male and 2 were female. The median age was 26 years, with a range of 21 to 51. There were 7 acute myeloid leukemia (AML), 3 non-Hodgkin's lymphoma (NHL) and 1 ovarian cancer. All patients received both chemotherapy and granulocyte-colony stimulating factor to mobilize hematopoietic stem cells, and the most commonly used conditioning regimen was combined chemotherapy with Busulfan and Cyclophosphamide. Results. The median numbers of infused mononuclear and CD34+ cells were 3.19 × 108/kg and 9.2 × 106/kg, respectively. Nine of the 11 patients engrafted successfully, but 2 patients with AML failed to engraft. The median times of WBC recovery (ANC ≥ 500/uL) and platelet recovery (≥ 20 × 103/uL) were 13 and 16 days, respectively. Four patients with AML survived after APBSCT and two of them were alive and disease-free for 36 and 51 months, respectively. One patient with AML and 3 patients with NHL died of relapse, and one patient with ovarian cancer was alive but with disease at 50 months. Conclusions. For patients with AML, APBSCT may be an alternative, safe and useful treatment modality. Further strategies for reducing relapse in lymphoma patients merit further investigation.

AB - Background. High-dose chemotherapy/radiotherapy followed by autologous peripheral blood stem cells transplantation (APBSCT) can be used to treat chemosensitive malignant diseases. We retrospectively studied the APBSCT treatment efficacy and safety of patients at Tri-Service General Hospital (TSGH). Methods. From January 1994 to March 2000, 11 patients were treated with high doses of chemotherapy/radiotherapy followed by APBSCT. Nine patients were male and 2 were female. The median age was 26 years, with a range of 21 to 51. There were 7 acute myeloid leukemia (AML), 3 non-Hodgkin's lymphoma (NHL) and 1 ovarian cancer. All patients received both chemotherapy and granulocyte-colony stimulating factor to mobilize hematopoietic stem cells, and the most commonly used conditioning regimen was combined chemotherapy with Busulfan and Cyclophosphamide. Results. The median numbers of infused mononuclear and CD34+ cells were 3.19 × 108/kg and 9.2 × 106/kg, respectively. Nine of the 11 patients engrafted successfully, but 2 patients with AML failed to engraft. The median times of WBC recovery (ANC ≥ 500/uL) and platelet recovery (≥ 20 × 103/uL) were 13 and 16 days, respectively. Four patients with AML survived after APBSCT and two of them were alive and disease-free for 36 and 51 months, respectively. One patient with AML and 3 patients with NHL died of relapse, and one patient with ovarian cancer was alive but with disease at 50 months. Conclusions. For patients with AML, APBSCT may be an alternative, safe and useful treatment modality. Further strategies for reducing relapse in lymphoma patients merit further investigation.

KW - Acute myeloid leukemia

KW - Autologous peripheral blood

KW - Non-Hodgkin's lymphoma

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0034815878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034815878&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 395

EP - 402

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 7

ER -